- Home
- SPRO vs PYPD Comparison
SPRO vs PYPD Comparison
Compare SPRO & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- PYPD
- Stock Information
- Founded
- SPRO 2013
- PYPD 2008
- Country
- SPRO United States
- PYPD Israel
- Employees
- SPRO N/A
- PYPD N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- SPRO Health Care
- PYPD Health Care
- Exchange
- SPRO Nasdaq
- PYPD Nasdaq
- Market Cap
- SPRO 33.0M
- PYPD 35.3M
- IPO Year
- SPRO 2017
- PYPD 2020
- Fundamental
- Price
- SPRO $3.02
- PYPD $3.28
- Analyst Decision
- SPRO Buy
- PYPD Strong Buy
- Analyst Count
- SPRO 4
- PYPD 5
- Target Price
- SPRO $5.00
- PYPD $11.40
- AVG Volume (30 Days)
- SPRO 12.5M
- PYPD 1.4M
- Earning Date
- SPRO 08-04-2025
- PYPD 08-13-2025
- Dividend Yield
- SPRO N/A
- PYPD N/A
- EPS Growth
- SPRO N/A
- PYPD N/A
- EPS
- SPRO N/A
- PYPD N/A
- Revenue
- SPRO $44,584,000.00
- PYPD N/A
- Revenue This Year
- SPRO N/A
- PYPD N/A
- Revenue Next Year
- SPRO N/A
- PYPD N/A
- P/E Ratio
- SPRO N/A
- PYPD N/A
- Revenue Growth
- SPRO N/A
- PYPD N/A
- 52 Week Low
- SPRO $0.51
- PYPD $2.30
- 52 Week High
- SPRO $3.06
- PYPD $4.49
- Technical
- Relative Strength Index (RSI)
- SPRO 79.94
- PYPD 54.91
- Support Level
- SPRO $2.81
- PYPD $3.33
- Resistance Level
- SPRO $3.06
- PYPD $3.71
- Average True Range (ATR)
- SPRO 0.24
- PYPD 0.30
- MACD
- SPRO -0.00
- PYPD 0.01
- Stochastic Oscillator
- SPRO 93.75
- PYPD 43.97
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.